Repro Med Systems Inc (REPR)

[blue_skies]

Xembify® is Grifols’ first 20% SCIg for the treatment of PIDD (1)
§ Grifols plans Q4 2019 U.S. launch, working to obtain
approvals in Canada, Europe and other global markets (1)
§ We view this as a positive development for RMS Medical,
patients, and the industry
§ Approval should help address Ig supply chain constraints
and expand market opportunities
§ We see a low-risk of cannibalization to Hizentra®
§ Collaborating with pharmaceutical companies is a primary
component of RMS Medical’s Strategic Plan

https://d1io3yog0oux5.cloudfront.net/_2f9331a575b029ed6973d4ed07f75ecb/rmsmedicalproducts/db/351/2392/presentation/REPR+Q2+2019+Investor+Call.pdf
page 11